C83.23 Mixed small and large cell (diffuse) non-Hodgkin's lymphoma, intra-abdominal lymph nodes

Name of the Condition

• Mixed small and large cell (diffuse) non-Hodgkin's lymphoma, intra-abdominal lymph nodes
• Also known as ICD-10 code C83.23

Summary

Mixed small and large cell (diffuse) non-Hodgkin's lymphoma is a subtype of non-Hodgkin lymphoma characterized by the malignant proliferation of both small and large lymphoid cells in a diffuse pattern. It typically involves abnormal growth of B-cells or T-cells in the intra-abdominal lymph nodes, without forming follicular structures. This condition is part of the broader category of non-follicular lymphomas and may present with variable clinical behavior depending on the specific cell composition and distribution.

Causes

The exact cause of mixed small and large cell (diffuse) non-Hodgkin's lymphoma remains unknown. It is thought to involve genetic mutations or abnormalities in lymphoid cell development, though specific triggers are not well-defined. Research suggests potential links to immune system dysregulation or prior infections, but no definitive etiology has been established.

Risk Factors

• Age: More common in older adults.
• Family history of lymphoma.
• Prior exposure to radiation or certain chemicals.
• Chronic infections, such as hepatitis C or HIV.
• Immunosuppressive conditions or treatments.

Symptoms

• Swollen, painless lymph nodes in the abdominal region.
• Unexplained weight loss.
• Fever.
• Night sweats.
• Abdominal pain or discomfort.
• Loss of appetite.

Diagnosis

Diagnosis typically involves a combination of physical examination, imaging studies (e.g., CT or MRI of the abdomen), and biopsy of the affected lymph nodes. Histopathological analysis confirms the presence of mixed small and large cell morphology in a diffuse pattern. Additional tests, such as flow cytometry or immunohistochemistry, may be used to identify cell type (B-cell or T-cell) and rule out other conditions. Staging studies, including PET scans, help determine the extent of disease.

Treatment Options

Treatment depends on the stage, cell type, and patient health. Common approaches include chemotherapy (e.g., CHOP or R-CHOP regimens), immunotherapy (e.g., monoclonal antibodies), and radiation therapy for localized disease. Stem cell transplantation may be considered for relapsed or high-risk cases. Clinical trials or targeted therapies may be options for some patients.

Prognosis and Follow-Up

Prognosis varies based on factors like stage, cell type, and response to treatment. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or progression. Long-term surveillance helps manage potential late effects of therapy.

Complications

• Disease progression or transformation to a more aggressive subtype.
• Treatment-related side effects (e.g., infection risk, organ toxicity).
• Metastasis to other lymph nodes or organs.
• Secondary malignancies from therapy.

Lifestyle & Prevention

• Maintain a healthy immune system through balanced nutrition and regular exercise.
• Avoid known carcinogens (e.g., tobacco, excessive alcohol).
• Manage chronic infections or immunosuppressive conditions under medical guidance.
• Follow recommended cancer screening guidelines.

When to Seek Professional Help

Seek medical attention for persistent abdominal swelling, unexplained weight loss, fever, or night sweats. Prompt evaluation is critical if symptoms worsen or new concerning signs (e.g., severe pain, jaundice) develop.

Tips for Medical Coders

Use C83.23 for cases of mixed small and large cell (diffuse) non-Hodgkin's lymphoma confirmed to involve intra-abdominal lymph nodes. Ensure documentation specifies the anatomical site and histological subtype to support code assignment. Verify that the diagnosis aligns with the diffuse, non-follicular pattern characteristic of this condition.